Mylan ($MYL) annoucend receiving tentative FDA approval for its Efavirenz, Lamivudine and Tenofovir Disproxil Fumarate Tablets, 400 mg/300 mg/300 mg, abbreviated as TLE40, for the first-line treatment of HIV-1 infection. The tentative approval is under the President’s Emergency Plan for AIDS Relief. The dose of efavirenz is 400 mg, lower than 600 mg dose in Bristol-Myers Squibb's Sustiva.
Pulmatrix ($PULM) announced that it has been awarded a new patent in he EU covering its drug delivery technology and its use in treating a range of diseases. The patent is similar to those already in place in the U.S. and Japan. The company’s new technology makes the delivery of dry powders more efficient.